Table 1. Patients characteristics and NGS results.

Patient	Sex	Age	Reads	Mean read length (bp)	Number of mapped reads	% reads on target (%)	Average reads per amplicon	Uniformity of amplicon coverage (%)	NRAS (allelic frequency)	BRAF (allelic frequency)	EGFR (allelic frequency)	KRAS (allelic frequency)
1	M	76	325,098	127	324,684	97.31	7,523	100.00	WT	WT	WT	WT
2	F	77	223,871	130	223,209	97.71	5,187	100.00	WT	WT	WT	WT
3	M	68	288,543	127	287,410	97.60	6,679	100.00	WT	WT	WT	WT
4	F	74	26,017	125	25,666	96.70	590.9	97.62	G12S (1.00%)	WT	WT	WT
5	F	36	163,218	128	162,752	98.06	3,800	97.62	WT	WT	WT	G12D (1.50%)
6	F	50	146,656	127	145,906	97.25	3,378	100.00	WT	V600A (0.20%)	WT	WT
7	M	70	173,021	127	172,314	97.55	4,002	97.62	G13D (0.34%)	WT	WT	Q61H (0.20%)
8	M	64	151,445	127	150,370	97.03	3,474	97.62	WT	WT	WT	G12C (1.30%)
9	M	61	75,353	127	74,972	97.68	1,744	97.62	WT	WT	WT	WT
10	M	45	190,620	126	189,708	97.49	4,403	100.00	WT	WT	H773_V774insH (37.0%)	WT
11	M	48	103,023	128	102,573	97.79	2,388	97.62	WT	WT	WT	G12C (0.60%)
12	F	61	163,363	128	162,841	97.75	3,790	97.62	WT	WT	WT	WT
13	F	57	130,596	128	130,250	97.72	3,031	97.62	WT	WT	WT	WT
14	F	51	155,551	128	155,018	97.40	3,595	97.62	WT	WT	WT	WT
15	M	62	60,927	128	60,611	97.77	1,411	97.62	WT	WT	V769_D770insASV (12.30%)	WT
16	F	87	67,571	128	67,404	97.85	1,570	97.62	WT	WT	WT	WT
17	F	77	181,295	129	180,633	98.06	4,217	95.24	WT	WT	WT	WT
18	M	75	104,653	127	104,925	97.79	2,429	97.62	WT	WT	WT	WT
19	M	58	262,771	130	261,202	97.94	6,091	97.62	WT	WT	WT	WT
20	F	38	248,897	128	248,287	97.68	5,775	97.62	WT	WT	WT	WT
21	F	51	169,989	128	169,581	97.44	9,734	97.62	WT	WT	WT	WT
22	M	64	36,774	128	36,693	97.84	854.7	97.62	WT	WT	WT	WT
23	M	74	195,245	128	194,624	97.50	4,518	100.00	WT	WT	L858R (3.20%)	WT
24	F	54	82,480	128	82,303	97.80	1,916	97.62	WT	WT	WT	WT
25	M	84	12,499	127	12,439	97.79	289.6	97.62	WT	WT	WT	WT
26	F	59	71,556	129	71,360	97.54	1,657	97.62	WT	WT	WT	G12D (1.30%)
27	M	68	62,909	128	62,723	97.61	1,458	97.62	WT	WT	WT	WT
28	M	56	51,993	128	51,453	97.44	1,194	100.00	WT	WT	WT	WT
29	M	89	21,306	127	21,126	97.12	488.5	97.62	WT	WT	WT	G12D
30	M	53	76	60	66	39.39	0.69	91.45	Failed	Failed	Failed	Failed
31	F	67	49,539	129	49,435	97.50	1,148	97.62	WT	G469A (5.00%)	WT	WT
32	M	62	113,202	130	112,930	98.01	2,635	97.62	WT	WT	WT	G12C (5.63%)
33	M	70	72,936	129	72,752	97.77	1,694	97.62	WT	WT	WT	WT
34	F	71	133,127	129	132,803	97.93	3,096	97.62	WT	WT	WT	WT
35	F	75	78,508	128	78,340	97.55	1,820	97.62	WT	WT	WT	WT
36	M	80	175,862	130	175,177	97.66	4,073	97.62	WT	WT	WT	WT
37	M	66	118,804	129	118,575	97.87	2,763	97.62	WT	WT	WT	WT
38	F	71	139,472	129	139,008	97.23	3,218	100.00	WT	WT	WT	WT
39	M	67	111,500	128	110,909	97.27	2,571	97.62	WT	WT	WT	WT
40	M	64	348,181	135	347,148	97.91	8,093	97.62	WT	WT	WT	G13S (0.20%)
41	M	80	131,590	129	131,257	97.98	3,062	97.62	WT	WT	WT	WT
42	M	80	141,018	129	140,564	98.15	3,285	97.62	Q61P (0.14%)	WT	WT	WT
43	F	76	72,635	128	72,364	97.77	1,685	97.62	WT	WT	WT	G13D (0.30%)
44	M	42	152,707	127	152,031	97.58	3,532	97.62	A59C (0.20%)	WT	WT	WT
45	M	66	74,945	127	74,630	97.64	1,735	97.62	WT	WT	WT	WT
46	F	57	50,945	128	50,607	97.58	1,176	97.62	WT	WT	WT	WT
47	M	67	84,001	130	83,802	97.69	1,949	97.62	WT	WT	WT	WT
48	M	69	133,275	132	132,908	97.57	3,087	97.62	WT	WT	WT	G12S (6.40%)
49	M	65	92,859	126	91,962	96.90	2,122	97.62	WT	WT	WT	G12C (3.30%)
50	M	77	47,845	130	47,653	97.32	1,104	97.62	WT	WT	WT	Q61H (4.50%)
51	M	82	23,283	129	23,118	97.44	5,363	97.62	WT	WT	WT	WT
52	F	77	31,713	129	31,599	97.86	9,363	97.62	WT	WT	WT	WT
53	M	84	121,037	129	120,379	97.44	2,793	97.62	WT	WT	WT	G13S (0.20%)
54	F	73	73,937	129	73,230	97.42	1,699	97.62	WT	WT	WT	WT
55	M	66	136,734	131	136,185	97.37	3,157	97.62	WT	WT	WT	WT
56	M	69	102,126	130	101,718	97.30	2,356	97.62	WT	WT	WT	WT
57	M	65	103,211	131	102,957	97.48	2,390	97.62	WT	WT	WT	WT
58	M	65	73,517	129	73,310	97.32	1,699	97.62	WT	WT	WT	WT
59	M	81	163,403	130	162,818	97.33	3,773	97.62	WT	WT	WT	WT
60	M	68	182,161	130	181,087	97.19	4,190	97.62	WT	WT	WT	WT
61	F	54	64,662	127	63,955	97.52	1,485	97.62	WT	WT	WT	WT
62	F	64	119,320	130	118,669	97.21	2,747	97.62	WT	WT	WT	A59V (0.20%)
63	F	67	103,023	128	102,573	97.79	2,388	97.62	WT	WT	ELREA (5.40%)	WT
64	F	61	173,021	127	172,314	97.55	4,002	97.62	WT	WT	ELREA (0.70%)	WT

Patients characteristics, SiRe^® next generation sequencing (NGS) panel run metric parameters (reads, mean read length in base pair, number of mapped reads, percentage of read on target, average reads per amplicon, uniformity of amplicon coverage) and genes mutational status with relative mutated allele frequency are reported for each sample.